Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to “wheat dextrin” and maintenance of normal blood pressure, maintenance of normal (fasting) blood concentrations of triglycerides, maintenance of normal blood cholesterol concentrations, reduction of post-prandial glycaemic responses, increase in magnesium and/or calcium retention, short chain fatty acid (SCFA) production in the bowel, decreasing potentially pathogenic gastro-intestinal microorganisms, and maintenance of normal bowel function. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claims is “wheat dextrin”. The Panel notes that the food constituent which is the subject of the health claims is a specific commercial preparation of wheat dextrin. The Panel considers that the food constituent, wheat dextrin in the specific preparation, which is the subject of this opinion is sufficiently characterised in relation to the claimed effects.
Scientific Opinion on the substantiation of health claims related to “wheat dextrin” and maintenance of normal blood pressure (ID 844, 1682), maintenance of normal (fasting) blood concentrations of triglycerides (ID 844, 1682), maintenance of normal blood cholesterol concentrations (ID 844, 1682), reduction of post-prandial glycaemic responses (ID 845, 3096), increase in magnesium and/or calcium retention (ID 846, 3097), short chain fatty acid (SCFA) production in the bowel (ID 1681), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 843, 1681) and maintenance of normal bowel function (ID 843, 1680) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 / C.V. Agostoni, J.L. Bresson, S. Fairweather Tait, A. Flynn, I. Golly, H. Korhonen, P. Lagiou, M. Løvik, R. Marchelli, A. Martin, B. Moseley, M. Neuhäuser Berthold, H. Przyrembel, S. Salminen, Y. Sanz, S. Strain, S. Strobel, I. Tetens, D. Tomé, H. van Loveren, H. Verhagen. - In: EFSA JOURNAL. - ISSN 1831-4732. - 8:10(2010). [10.2903/j.efsa.2010.1761]
Scientific Opinion on the substantiation of health claims related to “wheat dextrin” and maintenance of normal blood pressure (ID 844, 1682), maintenance of normal (fasting) blood concentrations of triglycerides (ID 844, 1682), maintenance of normal blood cholesterol concentrations (ID 844, 1682), reduction of post-prandial glycaemic responses (ID 845, 3096), increase in magnesium and/or calcium retention (ID 846, 3097), short chain fatty acid (SCFA) production in the bowel (ID 1681), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 843, 1681) and maintenance of normal bowel function (ID 843, 1680) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
C.V. AgostoniPrimo
;
2010
Abstract
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to “wheat dextrin” and maintenance of normal blood pressure, maintenance of normal (fasting) blood concentrations of triglycerides, maintenance of normal blood cholesterol concentrations, reduction of post-prandial glycaemic responses, increase in magnesium and/or calcium retention, short chain fatty acid (SCFA) production in the bowel, decreasing potentially pathogenic gastro-intestinal microorganisms, and maintenance of normal bowel function. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claims is “wheat dextrin”. The Panel notes that the food constituent which is the subject of the health claims is a specific commercial preparation of wheat dextrin. The Panel considers that the food constituent, wheat dextrin in the specific preparation, which is the subject of this opinion is sufficiently characterised in relation to the claimed effects.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
